Glenn Ramsey

Glenn Ramsey

Auto-generated profile, based on publicly available information

Glenn Ramsey

Department of Pathology Feinberg School of Medicine, Northwestern University Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2020 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
GRGlenn Ramsey
Glenn Ramsey
Background and objectives The US AABB disaster task force recommends estimating 3 RBC units per admission (UPA) for mass casualty events (MCEs). In a previous analysis, median MCE UPA were 2·7 RBCs, 1·2 plasmas and 0·27 platelet doses (Vox Sang 2017; 112:648). Additional recent data were sought from the current era of balanced massive transfusion protocols (bMTPs). Materials and methods Publications in English from 1980 to 2020 were reviewed for MCEs using ≥50 RBCs/event and with numbers of admissions available. MCE reports were stratified by era and event‐wide or trauma‐centre source. The bMTP era included all MCEs since 2010 plus a 2008 bMTP military report. Statistics: Mann–Whitney test. Results Thirty‐two MCEs met analysis criteria. Event‐wide reports used medians [interquartile ranges] of 1·8 [1·2–3·9] RBC, 0·6 [0·3–0·9] plasma and 0·14 [0·06–0·26] platelet‐dose UPA. Trauma centres transfused 3·4 [2·7–6·3] RBC, 2·4 [1·3–4·1] plasma and 0·41 [0·34–0·50] platelet‐dose UPA, all P < 0·05 vs event‐wide. Same‐event median post‐day‐1 transfusions were 50% of day‐1 use for RBC, 28% for plasma and 16% for platelets. Compared to prior years, the median plasma/RBC transfusion ratio rose from 0·28 to 0·67 in the bMTP era (P < 0·01). In recent mass shootings, trauma centres transfused up to 42 platelets (range 0·45–0·57 UPA) on day 1. Conclusion Based on available mass casualty data, we recommend planning for 3 RBC, 1 plasma and one‐fourth platelet‐dose units per admission for blood centres (event‐wide), and 6, 4 and one‐half UPA, respectively, for trauma centres, which have seen rising plasma usage and large mass‐shooting platelet needs.

27 July 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
OAOmar Al-Heeti
Omar Al-Heeti
EWEn-Ling Wu
En-Ling Wu
MIMichael G Ison
Michael G Ison
RSRasleen K Saluja
Rasleen K Saluja
GRGlenn Ramsey
Glenn Ramsey
STSajal Tanna
Sajal Tanna
Background: Cache Valley virus (CVV) is a mosquito-borne virus that is a rare cause of disease in humans. In the fall of 2020, a patient developed encephalitis 6 weeks following kidney transplantation and receipt of multiple blood transfusions. Methods: After ruling out more common etiologies, metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) was performed. We reviewed the medical histories of the index kidney recipient, organ donor, and recipients of other organs from the same donor and conducted a blood traceback investigation to evaluate blood transfusion as a possible source of infection in the kidney recipient. We tested patient specimens using reverse-transcription polymerase chain reaction (RT-PCR), the plaque reduction neutralization test, cell culture, and whole-genome sequencing. Results: CVV was detected in CSF from the index patient by mNGS, and this result was confirmed by RT-PCR, viral culture, and additional whole-genome sequencing. The organ donor and other organ recipients had no evidence of infection with CVV by molecular or serologic testing. Neutralizing antibodies against CVV were detected in serum from a donor of red blood cells received by the index patient immediately prior to transplant. CVV neutralizing antibodies were also detected in serum from a patient who received the co-component plasma from the same blood donation. Conclusions: Our investigation demonstrates probable CVV transmission through blood transfusion. Clinicians should consider arboviral infections in unexplained meningoencephalitis after blood transfusion or organ transplantation. The use of mNGS might facilitate detection of rare, unexpected infections, particularly in immunocompromised patients.

12 August 2024 in Transfusion
Verified
Journal Article
Closed access
EGEric A. Gehrie
Eric A. Gehrie
PYPampee P. Young
Pampee P. Young
SBSridhar V. Basavaraju
Sridhar V. Basavaraju
ABArthur W. Bracey
Arthur W. Bracey
ACAndrew P. Cap
Andrew P. Cap
ESEdward L. Snyder
Edward L. Snyder

11 October 2022 in Transfusion
Verified
Journal Article
Open access
CBChristina M. Barriteau
Christina M. Barriteau
PLPaul F. Lindholm
Paul F. Lindholm
KHKaryn Hartman
Karyn Hartman
RSRicardo D. Sumugod
Ricardo D. Sumugod
GRGlenn Ramsey
Glenn Ramsey
Background: We instituted RHD genotyping in our transfusion service for obstetrical patients and transfusion candidates. We sought to examine how RHD genotyping resolved weak or discrepant automated microplate direct agglutination (MDA) RhD phenotypings and impacted needs for Rh Immune Globulin (RhIG) and D‐negative RBCs.Study Design and Methods: We investigated RhD phenotypes with equivocal or reagent‐discrepant automated MDA (Immucor, Norcross, GA), weak‐2+ immediate‐spin tube typings, historically discrepant RhD typings, or D+ typings with anti‐D. We performed microarray RHD genotyping (RHD BeadChip, Immucor BioArray Solutions, Warren, NJ). Patients were managed as D+ with weak‐D types 1, 2, and 3, and as D‐negative with all other results.Results: Our weak‐D prevalence was 0.14%. Among 138 patients (73 obstetrics, 65 transfusion candidates), 38% had weak‐D types 1, 2 or 3, 25% weak partial type 4.0, 21% other partial‐D variant alleles, and 15% no variant detected. One novel allele with weak partial type 4.0 variants plus c.150T>C (Val50Val) was discovered. Weak D types 1, 2 or 3 were identified in 66% (48/73) of Whites versus 3% (2/62) of diverse ethnic patients (p < .0001). RHD genotyping changed RhD management in 60 patients (43%) (49 to D+, 11 to D‐negative), resulting in net conservation of D‐negative RBCs (98 avoided, 14 given) and RhIG (8 avoided, 3 given).Conclusion: In our patient population, equivocal or reagent‐discrepant MDA RhD phenotypes were highly specific for weak‐D or partial‐D RHD genotypes. Resolution of RHD genotype status reduced our use of D‐negative RBCs and RhIG.

10 September 2017 in Vox Sanguinis
Verified
Journal Article
Closed access
PDF file
GRG. Ramsey
G. Ramsey

2 May 2022 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
PDF file
GRGlenn Ramsey
Glenn Ramsey
YPYara A. Park
Yara A. Park
AEAnne F. Eder
Anne F. Eder
ABAleh Bobr
Aleh Bobr
MKMatthew S. Karafin
Matthew S. Karafin
MDMeghan Delaney
Meghan Delaney
Context.—: Modern RHD genotyping can be used to determine when patients with serologic weak D phenotypes have RHD gene variants at risk for anti-D alloimmunization. However, serologic testing, RhD interpretations, and laboratory management of these patients are quite variable. Objective.—: To obtain interlaboratory comparisons of serologic testing, RhD interpretations, Rh immune globulin (RhIG) management, fetomaternal hemorrhage testing, and RHD genotyping for weak D-reactive specimens. Design.—: We devised an educational exercise in which 81 transfusion services supporting obstetrics performed tube-method RhD typing on 2 unknown red blood cell challenge specimens identified as (1) maternal and (2) newborn. Both specimens were from the same weak D-reactive donor. The exercise revealed how participants responded to these different clinical situations. Results.—: Of reporting laboratories, 14% (11 of 80) obtained discrepant immediate-spin reactions on the 2 specimens. Nine different reporting terms were used to interpret weak D-reactive maternal RhD types to obstetricians. In laboratories obtaining negative maternal immediate-spin reactions, 28% (16 of 57) performed unwarranted antiglobulin testing, sometimes leading to recommendations against giving RhIG. To screen for excess fetomaternal hemorrhage after a weak D-reactive newborn, 47% (34 of 73) of reporting laboratories would have employed a contraindicated fetal rosette test, risking false-negative results and inadequate RhIG coverage. Sixty percent (44 of 73) of laboratories would obtain RHD genotyping in some or all cases. Conclusions.—: For obstetric and neonatal patients with serologic weak D phenotypes, we found several critical problems in transfusion service laboratory practices. We provide recommendations for appropriate testing, consistent immunohematologic terminology, and RHD genotype–guided management of Rh immune globulin therapy and RBC transfusions.